Navigation Links
HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
Date:5/10/2013

FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013.  The conference is being held May 14-16, 2013 at the Encore at Wynn in Las Vegas.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 30 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

 


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
2. HeartWare Schedules First Quarter Conference Call And Webcast
3. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
4. HeartWare International, Inc. Announces Public Offering of Common Stock
5. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
6. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
7. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
8. HeartWare Schedules Fourth Quarter Conference Call and Webcast
9. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
10. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
11. HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, Embodied ... Startups pitch competition and came away with $25,000 ... is described by Forbes as "entering the life of ... Association as teaching "empathy to medical professionals in an ... was recently named a finalist for the Department of ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... London UK (PRWEB) , ... June 27, 2017 , ... ... a clinical study is whether they can trust the sponsor to pay them correctly ... vital that sponsors and CROs establish payment strategies that encourage sites to work on ...
(Date:6/27/2017)... ... , ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation ... and Affordable Care Act (ACA), would result in 22 million Americans losing their health ... More than 20 million Americans have gained health insurance under the ACA, and from ...
(Date:6/27/2017)... ... 27, 2017 , ... A January 18th article on medGadget reports ... billion by the year 2024 according to a new report. The article also notes ... from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
Breaking Medicine News(10 mins):